Carl L. Gordon - Jun 13, 2022 Form 4 Insider Report for Kinnate Biopharma Inc. (KNTE)

Role: Director
Signature: /s/ Mark A. Meltz, as attorney-in-fact
Stock symbol: KNTE
Transactions as of: Jun 13, 2022
Transactions value $: $0
Form type: 4
Date filed: 6/15/2022, 05:00 PM
Previous filing: Jun 13, 2022
Next filing: Jun 21, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KNTE	Stock Option (right to buy)	Award	$0	+20.3K		$0.00	20.3K	Jun 13, 2022	Common Stock	20.3K	$8.38	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	1/12th of the shares underlying the Option vest and become exercisable on a monthly basis starting July 13, 2022 (the Vest Base Date) and thereafter on the same day of the month as the Vest Base Date or if earlier, the day immediately before the date of the next Annual Meeting of Stockholders that occurs after the Vest Base Date.
F2	Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VII, LP.

Content

1/12th of the shares underlying the Option vest and become exercisable on a monthly basis starting July 13, 2022 (the Vest Base Date) and thereafter on the same day of the month as the Vest Base Date or if earlier, the day immediately before the date of the next Annual Meeting of Stockholders that occurs after the Vest Base Date.

Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VII, LP.